| Michael Ray Holtel, MD | |
|
10670 Wexford St, San Diego, CA 92131-3940 | |
| (858) 621-4090 | |
| (858) 621-4044 |
| Full Name | Michael Ray Holtel |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 40 Years |
| Location | 10670 Wexford St, San Diego, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073584397 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | G59182 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sharp Memorial Hospital | San diego, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sharp Rees-stealy Medical Group Inc | 8628972759 | 772 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.
People with a certain form of inherited hearing loss have increased sensitivity to low frequency vibration, according to a study by Professor Thomas Jentsch of the Leibniz-Institut f-r Molekulare Pharmakologie (FMP)/Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and Professor Gary Lewin (MDC), conducted in cooperation with clinicians from Madrid, Spain and Nijmegen, the Netherlands.
Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."
The move by California's largest insurer for small businesses raised concerns about the state's ability to offer competitive rates. Meanwhile, Humana will step in to fill a potential insurance void in Mississippi, offering coverage in 36 counties where no other plans had been slated to be sold.
› Verified 6 days ago
| Entity Name | Sharp Rees-stealy Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285616177 PECOS PAC ID: 8628972759 Enrollment ID: O20031120000996 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.
People with a certain form of inherited hearing loss have increased sensitivity to low frequency vibration, according to a study by Professor Thomas Jentsch of the Leibniz-Institut f-r Molekulare Pharmakologie (FMP)/Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and Professor Gary Lewin (MDC), conducted in cooperation with clinicians from Madrid, Spain and Nijmegen, the Netherlands.
Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."
The move by California's largest insurer for small businesses raised concerns about the state's ability to offer competitive rates. Meanwhile, Humana will step in to fill a potential insurance void in Mississippi, offering coverage in 36 counties where no other plans had been slated to be sold.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Ray Holtel, MD 10670 Wexford St, San Diego, CA 92131-3940 Ph: (858) 621-4090 | Michael Ray Holtel, MD 10670 Wexford St, San Diego, CA 92131-3940 Ph: (858) 621-4090 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.
People with a certain form of inherited hearing loss have increased sensitivity to low frequency vibration, according to a study by Professor Thomas Jentsch of the Leibniz-Institut f-r Molekulare Pharmakologie (FMP)/Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and Professor Gary Lewin (MDC), conducted in cooperation with clinicians from Madrid, Spain and Nijmegen, the Netherlands.
Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."
The move by California's largest insurer for small businesses raised concerns about the state's ability to offer competitive rates. Meanwhile, Humana will step in to fill a potential insurance void in Mississippi, offering coverage in 36 counties where no other plans had been slated to be sold.
› Verified 6 days ago
Dr. Jesse Raia Qualliotine, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 200 W Arbor Dr, San Diego, CA 92103 Phone: 800-926-8273 Fax: 888-539-8781 | |
Sapideh Gilani, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr # Mc8895, Division Of Otolaryngology Ucsd, San Diego, CA 92103 Phone: 619-543-7895 | |
Dr. Sassan Alavi, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 3023 Bunker Hill St, Suite 204, San Diego, CA 92109 Phone: 858-483-0690 | |
Dr. Kevin Thomas Brumund, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 200 W Arbor Dr Dept 8895, San Diego, CA 92103 Phone: 619-543-5910 Fax: 619-543-5521 | |
Pierre G. Rivet, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 4033 3rd Ave, Suite 104, San Diego, CA 92103 Phone: 619-294-2350 Fax: 619-296-5719 | |
Ronald T. Benz, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 10243 Genetic Center Dr, San Diego, CA 92121 Phone: 858-526-6136 Fax: 858-526-6117 | |
Dr. Jeffrey Watson, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3350 La Jolla Village Dr, M/c 9112-c, San Diego, CA 92161 Phone: 858-642-3637 |